# Chemotherapy and Erlotinib for Lung Cancer With Low Abundance Epidermal Growth Factor Receptor Mutation

> **NCT02095782** · PHASE2 · TERMINATED · sponsor: **Guangdong Association of Clinical Trials** · enrollment: 10 (actual)

## Conditions studied

- Non-small-cell Lung Cancer

## Interventions

- **DRUG:** Intercalated combination of chemotherapy and erlotinib

## Key facts

- **NCT ID:** NCT02095782
- **Lead sponsor:** Guangdong Association of Clinical Trials
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2014-03
- **Primary completion:** 2017-01-20
- **Final completion:** 2017-01-20
- **Target enrollment:** 10 (ACTUAL)
- **Why stopped:** Because of the very slow enrollment, this study was stopped.
- **Last updated:** 2017-03-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02095782

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02095782, "Chemotherapy and Erlotinib for Lung Cancer With Low Abundance Epidermal Growth Factor Receptor Mutation". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT02095782. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*